John J. Canepa - 28 Feb 2022 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Reporting relationship: Chief Financial Officer
Issuer ticker: CADL
Reported as of: 28 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Mar 2022, 17:40:38 UTC
Prior SEC filing: 02 Aug 2021
Source filing: View source filing
Reporting owner signature: /s/ John Canepa

Filing notes and source

Key filing fact

John J. Canepa filed Form 4 for Candel Therapeutics, Inc. (CADL) on 01 Mar 2022.

Key facts

This page summarizes John J. Canepa's Form 4 filing for Candel Therapeutics, Inc. (CADL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Mar 2022, 17:40.

Change

Previous filing in this sequence was filed on 02 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CADL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +110,000
Change %
Price: $0.000000
Shares after: 110,000
Date: 28 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 110,000
Exercise price: $4.12
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option is subject to time-based and performance-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following the Grant Date, subject to the Reporting Person's continued service on each such vesting date; provided, however, that one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $13.50 for any ten consecutive trading days prior to or as of December 31, 2022, and an additional one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $20.00 for any ten consecutive trading days prior to or as of December 31, 2022.